Delayed
Canadian Securities Exchange
14:58:51 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.97
CAD
|
-3.96%
|
|
+1.04%
|
+155.26%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
19.43
|
5.714
|
9.735
|
15.5
|
18.25
|
52.17
|
Enterprise Value (EV)
1 |
21.08
|
7.927
|
11.59
|
18.35
|
21.57
|
51.59
|
P/E ratio
|
-0
x
|
-0.59
x
|
-3.59
x
|
-5.1
x
|
40.4
x
|
-92.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.1
x
|
1.46
x
|
2.3
x
|
1.65
x
|
1.03
x
|
2.39
x
|
EV / Revenue
|
10.9
x
|
2.02
x
|
2.73
x
|
1.96
x
|
1.21
x
|
2.36
x
|
EV / EBITDA
|
-5.04
x
|
-2.02
x
|
-14.8
x
|
9.99
x
|
9.81
x
|
10.4
x
|
EV / FCF
|
-11.1
x
|
-2.84
x
|
-7.83
x
|
-4.2
x
|
-42.8
x
|
6.42
x
|
FCF Yield
|
-9.01%
|
-35.2%
|
-12.8%
|
-23.8%
|
-2.34%
|
15.6%
|
Price to Book
|
-0
x
|
-3.89
x
|
-10.7
x
|
2.81
x
|
2.63
x
|
4.24
x
|
Nbr of stocks (in thousands)
|
71,654
|
74,279
|
107,823
|
170,415
|
170,633
|
182,006
|
Reference price
2 |
0.2712
|
0.0769
|
0.0903
|
0.0910
|
0.1069
|
0.2866
|
Announcement Date
|
01/03/19
|
20/03/20
|
01/03/21
|
28/02/22
|
28/02/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1.932
|
3.925
|
4.24
|
9.379
|
17.76
|
21.83
|
EBITDA
1 |
-4.187
|
-3.921
|
-0.7847
|
1.836
|
2.2
|
4.974
|
EBIT
1 |
-4.65
|
-4.016
|
-0.9653
|
1.651
|
1.449
|
3.856
|
Operating Margin
|
-240.66%
|
-102.32%
|
-22.77%
|
17.61%
|
8.16%
|
17.66%
|
Earnings before Tax (EBT)
1 |
-7.51
|
-9.477
|
-2.356
|
-0.8642
|
0.6653
|
6.336
|
Net income
1 |
-7.51
|
-9.3
|
-2.281
|
-2.41
|
0.4475
|
3.857
|
Net margin
|
-388.69%
|
-236.95%
|
-53.81%
|
-25.7%
|
2.52%
|
17.67%
|
EPS
2 |
-712.2
|
-0.1311
|
-0.0252
|
-0.0178
|
0.002644
|
-0.003086
|
Free Cash Flow
1 |
-1.899
|
-2.792
|
-1.48
|
-4.367
|
-0.5043
|
8.033
|
FCF margin
|
-98.29%
|
-71.13%
|
-34.9%
|
-46.56%
|
-2.84%
|
36.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
161.49%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
208.27%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/03/19
|
20/03/20
|
01/03/21
|
28/02/22
|
28/02/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1.65
|
2.21
|
1.85
|
2.85
|
3.33
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
0.58
|
Leverage (Debt/EBITDA)
|
-0.3942
x
|
-0.5643
x
|
-2.362
x
|
1.55
x
|
1.513
x
|
-
|
Free Cash Flow
1 |
-1.9
|
-2.79
|
-1.48
|
-4.37
|
-0.5
|
8.03
|
ROE (net income / shareholders' equity)
|
2,731%
|
1,131%
|
199%
|
-32.9%
|
5.23%
|
-6.16%
|
ROA (Net income/ Total Assets)
|
-70.2%
|
-60.5%
|
-18%
|
11.5%
|
5.92%
|
14.2%
|
Assets
1 |
10.7
|
15.37
|
12.66
|
-20.99
|
7.555
|
27.19
|
Book Value Per Share
2 |
-144.0
|
-0.0200
|
-0.0100
|
0.0300
|
0.0400
|
0.0700
|
Cash Flow per Share
2 |
78.40
|
0
|
0
|
0.0100
|
0.0100
|
0.0400
|
Capex
1 |
1.06
|
0.22
|
0.56
|
2.05
|
1.11
|
0.76
|
Capex / Sales
|
54.65%
|
5.51%
|
13.16%
|
21.83%
|
6.26%
|
3.48%
|
Announcement Date
|
01/03/19
|
20/03/20
|
01/03/21
|
28/02/22
|
28/02/23
|
30/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +155.26% | 155M | | +45.15% | 6.38B | | -14.00% | 4.59B | | +9.54% | 3.39B | | -8.99% | 3.2B | | -2.41% | 2.52B | | +50.03% | 2B | | -6.97% | 1.7B | | -0.31% | 1.65B | | -10.61% | 1.58B |
Alternative Medicine
|